• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Infection

tetano

Editor, Senior Moderator
Antimicrob Agents Chemother. 2015 Jul 27. pii: AAC.01098-15. [Epub ahead of print]
[h=1]The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Infection.[/h] Traboulsi H[SUP]1[/SUP], Cloutier A[SUP]2[/SUP], Boyapelly K[SUP]3[/SUP], Bonin MA[SUP]3[/SUP], Marsault ?[SUP]3[/SUP], Cantin AM[SUP]2[/SUP], Richter MV[SUP]4[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The host response to influenza virus infection is characterized by an acute lung inflammatory response in which intense inflammatory cell recruitment, hypercytokinemia, and high level of oxidative stress are present. The sum of these events contributes to the virus-induced lung damage that leads to high a level of morbidity and mortality in susceptible infected patients. In this context, we identified compounds that can simultaneously reduce the excessive inflammatory response and the viral replication as a strategy to treat influenza infection. We investigated the anti-inflammatory and antiviral potential activities of isoliquiritigenin (ILG). Interestingly, we demonstrated that ILG is a potent inhibitor of influenza virus replication in human bronchial epithelial cells (EC[SUB]50[/SUB]= 24.7μM). In addition, our results showed that this molecule inhibits the expression of inflammatory cytokines induced after the infection of cells with the influenza virus. We demonstrated that the anti-inflammatory activity of ILG in the context of influenza infection is dependent on the activation of the peroxisome proliferator-activated receptor gamma pathway. Interestingly, ILG-phosphate (ILG-p)-treated mice displayed decreased lung inflammation as depicted by reduced cytokine gene expression and inflammatory cell recruitment. We also demonstrated that influenza-specific CD8[SUP]+[/SUP] effector T cell recruitment was reduced up to 60% in the lungs of mice treated with ILG-p (10 mg/kg) compared to saline-treated mice. Finally, we showed that administration of ILG-p reduced lung viral titers and morbidity of mice infected with the PR8/H1N1 virus.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.


PMID: 26248373 [PubMed - as supplied by publisher]
 
Back
Top Bottom